From Roche Pays $120M for Rights to UCB’s Tau-Targeting Alzheimer’s Drug:

white-human-brain-picture-id627014070

white-human-brain-picture-id627014070—

Underwriters and Partners

Xconomy Insight

From Our Editors · Special Report
Xcelerating Life Sciences San Francisco: Special Report
The AI, Big Data, and R&D Boom

Sponsored · Whitepaper
CMC in Drug Development and Life Cycle Management
CMC in Drug Development and Life Cycle Management
PRA Health Sciences

Sponsored · Webinar
Oct. 28 – Accelerating COVID-19 Drug Discovery: Qualified Assays for Proinflammatory Cytokines
How Functional Cell-based Assays Support Clinical Programs Managing Proinflammatory Cytokines Associated with High Mortality
Eurofins DiscoverX

Xconomy on Demand

We offer a number of ways to subscribe for free!